Sonnet Biotherapeutics Holdings (SONN) falls over 5% today
Sonnet Biotherapeutics Holdings (SONN) currently trades at $5.75 and has fallen by 5.58% today. SONN went down $0.34 from the previous closing price of $6.09. The high forecast for Sonnet Biotherapeutics Holdings is $30.00 and the low is $10.00. The company’s market cap is $52.85 million with a 52 week high of $76.70 and a 52 week low of $4.61. SONN has changed in price by -35.86 per share in the last 12 months.
Sonnet Biotherapeutics Holdings has a weak EPS of -2.35. This means the company lost $-2.35 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information written in this article.
About Sonnet Biotherapeutics Holdings:
SONNET BioTherapeutics, Inc. is a biotechnology company that engages in development of bi and tri functional therapies that can simulate or block immune-modulating targets to control cancer.